Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
13 pending office actions • 11 clients • 13 examiners • 13 art units • 0 of 13 (0%) have an AI response strategy ready
Adler Pollock & Sheehan P.C. focuses on Biotechnology & Pharmaceuticals and has 12 pending office actions. Its prosecution record includes 1387 career applications, supplying a substantial base for interpreting the reported results.
The resolved allowance rate is 87.75%, and applications reaching allowance have averaged 2.92 office actions. The profile indicates favorable resolved outcomes with successful applications generally requiring multiple stages of examination and response.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (31%) |
| §103 only | 1 (8%) |
| §112 only | 2 (15%) |
| Multi-statute (no §101) | 6 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORTIZ, ADAM C | 1 | 65.8% | +34.7% |
| CHANG, OLIVIA C | 1 | 84.6% | +13.1% |
| MORALES, JON ERIC C | 1 | 85.4% | +10.0% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 71.4% | +0.0% |
| STIGELL, THEODORE J | 1 | 78.3% | +14.8% |
| YU, TIAN NMN | 1 | 55.6% | +19.3% |
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
| LING, DORIS | 1 | 25.0% | +27.3% |
| WALTERS JR, ROBERT S | 1 | 51.6% | +50.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996489 | TIME-RESOLVING HYPERSPECTRAL IMAGING SPECTROSCOPY | SMITH, DAVID E | 97d overdue |
| 19248266 | LEVELING INFANT BED | ORTIZ, ADAM C | — |
| 18970680 | FUSION PLATE TO ASSIST FUSION OF A FIRST AND SECOND BONE | CHANG, OLIVIA C | — |
| 18951376 | HUMAN-POWERED STIMULATING/SENSING IMPLANT SYSTEM | MORALES, JON ERIC C | — |
| 18708467 | PREDICTING COVID-19 ANTIBODIES AMONG SURVIVORS WITH DEEP RNA SEQUENCING | CORNELIUS, CLAIRE ADRIENNE | — |
| 18528750 | USING DEEP RNA SEQUENCING DATA TO IDENTIFY ANTIMICROBIAL-RESISTANT BACTERIA | YU, TIAN NMN | — |
| 18557561 | DECELLULARIZED TISSUE HYDROGELS | BOECKELMAN, JACOB A | — |
| 18286985 | ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK | PIHONAK, SARAH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18638615 | ACCESS PORT SYSTEM WITH SELF-ADJUSTING CATHETER LENGTH | STIGELL, THEODORE J | 84d overdue |
| 19248266 | LEVELING INFANT BED | ORTIZ, ADAM C | — |
| 18970680 | FUSION PLATE TO ASSIST FUSION OF A FIRST AND SECOND BONE | CHANG, OLIVIA C | — |
| 18951376 | HUMAN-POWERED STIMULATING/SENSING IMPLANT SYSTEM | MORALES, JON ERIC C | — |
| 18528750 | USING DEEP RNA SEQUENCING DATA TO IDENTIFY ANTIMICROBIAL-RESISTANT BACTERIA | YU, TIAN NMN | — |
| 18557561 | DECELLULARIZED TISSUE HYDROGELS | BOECKELMAN, JACOB A | — |
| 18286985 | ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK | PIHONAK, SARAH | — |
| 18552887 | WEAR LAYER COMPOSITIONS | LING, DORIS | — |
| Art Unit | Apps |
|---|---|
| 3673 | 1 |
| 3775 | 1 |
| 3796 | 1 |
| 1672 | 1 |
| 3783 | 1 |
| 1681 | 1 |
| 1655 | 1 |
| 1627 | 1 |
| 1764 | 1 |
| 1717 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19248266 | LEVELING INFANT BED | Kids2, LLC | ORTIZ, ADAM C | 3673 | §103§112 | Final Rejection | — | Pending | Jun 24, 2025 |
| 18970680 | FUSION PLATE TO ASSIST FUSION OF A FIRST AND SECOND BONE | Arc Techtonics, Inc. | CHANG, OLIVIA C | 3775 | §102§112 | Non-Final OA | — | Pending | Dec 05, 2024 |
| 18951376 | HUMAN-POWERED STIMULATING/SENSING IMPLANT SYSTEM | Evoke Medical, LLC Dba Directsync Surgical | MORALES, JON ERIC C | 3796 | §101§102§103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18708467 | PREDICTING COVID-19 ANTIBODIES AMONG SURVIVORS WITH DEEP RNA SEQUENCING | Rhode Island Hospital | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§102§103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18638615 | ACCESS PORT SYSTEM WITH SELF-ADJUSTING CATHETER LENGTH | Imotik Biosolutions LLC | STIGELL, THEODORE J | 3783 | §103 | Non-Final OA | 84d overdue | Pending | Apr 17, 2024 |
| 18528750 | USING DEEP RNA SEQUENCING DATA TO IDENTIFY ANTIMICROBIAL-RESISTANT BACTERIA | Rhode Island Hospital | YU, TIAN NMN | 1681 | §101§103§112 | Final Rejection | — | Pending | Dec 04, 2023 |
| 18557561 | DECELLULARIZED TISSUE HYDROGELS | The University of Nottingham | BOECKELMAN, JACOB A | 1655 | §101§102§103§112 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18286985 | ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK | Applied Biology, Inc. | PIHONAK, SARAH | 1627 | §102§103§112Other | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18552887 | WEAR LAYER COMPOSITIONS | Bixby International Corporataion | LING, DORIS | 1764 | §102§103§112 | Final Rejection | — | Pending | Sep 27, 2023 |
| 18341067 | DENTAL ALIGNER | BIXBY INTERNATIONAL CORPORATION | WALTERS JR, ROBERT S | 1717 | §112 | Non-Final OA | — | Pending | Jun 26, 2023 |
| 18314803 | CARTILAGE-DERIVED PROGENITOR CELL LINES | Rhode Island Hospital | STAVROU, CONSTANTINA E | 1632 | §102§103 | Final Rejection | — | Pending | May 09, 2023 |
| 17996489 | TIME-RESOLVING HYPERSPECTRAL IMAGING SPECTROSCOPY | Research Instruments Corporation | SMITH, DAVID E | 2881 | §102§103 | Final Rejection | 97d overdue | Pending | Oct 18, 2022 |
| 17933986 | APPARATUS, METHOD, SYSTEM FOR THE DETERMINATION OF BLOODBORNE FACTORS INDICATIVE OF INFLAMMATION | Alcor Scientific LLC | TURK, NEIL N | 1798 | §112Other | Final Rejection | 4d overdue | Pending | Sep 21, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial87.8% of resolved applications prosecuted by Adler, Pollock & Sheehan, P.C. were allowed, across 1,387 applications in USPTO records.
2.92 office actions per allowed application on average.
13 pending office actions as of October 2026, for 11 clients, before 13 examiners in 13 art units.
